{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"2","value":"1"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"1","value":"0"}]}],"title":"Death at or before study Visit"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12","upperLimit":"19","value":"15"},{"groupId":"OG001","lowerLimit":"15","upperLimit":"21","value":"18"}]}],"title":"Hospitalized, on invasive mech. vent. or ECMO"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"20","value":"17"},{"groupId":"OG001","lowerLimit":"15","upperLimit":"22","value":"18"}]}],"title":"Hospitalized, on non-invasive vent./high flow O2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31","upperLimit":"39","value":"35"},{"groupId":"OG001","lowerLimit":"29","upperLimit":"37","value":"33"}]}],"title":"Hospitalized, requiring supplemental oxygen"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"22","value":"19"},{"groupId":"OG001","lowerLimit":"12","upperLimit":"18","value":"15"}]}],"title":"Hospitalized, not on O2, requiring ongoing care"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"2","value":"1"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"2","value":"1"}]}],"title":"Hospitalized, not requiring O2, no longer req care"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"1","value":"0.2"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"1","value":"0"}]}],"title":"Not hospitalized, limit on activities/req home O2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"1","value":"0.2"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"1","value":"0"}]}],"title":"Not hospitalized, no limitations on activities"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"1","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"1","value":"0.2"}]}],"title":"No clinical status score reported - Hospitalized"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"13","value":"10"},{"groupId":"OG001","lowerLimit":"10","upperLimit":"16","value":"13"}]}],"title":"No clinical status score reported - Discharged"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"4","value":"2"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"5","value":"3"}]}],"title":"No clinical status score reported - Discontinued"}],"denoms":[{"counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"518"}],"units":"Participants"}],"description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"NUMBER","populationDescription":"The intent-to-treat (ITT) population includes all participants who were randomized","reportingStatus":"POSTED","timeFrame":"Day 5","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5","type":"SECONDARY","unitOfMeasure":"percentage of participants"}